AB Science to Host Live Webcast on Masitinib Developments
AB Science SA, recognized for its innovative approach to pharmaceuticals, is preparing to host an engaging live webcast. This event, which will take place on the 28th of January, will serve as a significant platform to discuss advances in their leading drug, masitinib. Setting innovative standards in the pharmaceutical industry, AB Science aims to create in-depth discussions surrounding its drug development strategies and future possibilities.
What to Expect from the Webcast
The forthcoming webcast is scheduled from 5:30 PM to 6:45 PM CET. It promises to deliver valuable insights into the masitinib platform, which is at the forefront of AB Science's ongoing research and development efforts. This event is anticipated to attract a diverse audience eager to learn about the breakthroughs made in the company's drug innovation journey.
Key Participants in the Webcast
Alain Moussy, co-founder and CEO of AB Science, will lead the discussion, supported by the expertise of Olivier Hermine, MD, PhD, the Head of the Hematological Department at the Necker-Enfants Malades Hospital in Paris. Their combined knowledge will shed light on the importance of masitinib in treating diseases that often have limited options, particularly in the hematology field.
About Masitinib and Its Potential
Masitinib is a pioneering protein kinase inhibitor (PKI) being developed by AB Science, especially in oncology and other serious medical conditions like neurological and inflammatory disorders. The company has established itself as a leader in addressing high unmet medical needs, often targeting diseases that are lethal or refractory to traditional treatments.
Understanding the Agenda
The agenda is expected to focus heavily on updates related to masitinib, emphasizing its significance and the progress AB Science has made in various therapeutic areas. Given the company's mission to cater to critical health needs, this discussion will be particularly relevant for stakeholders and individuals invested in the future of medicine.
Get Involved in the Live Event
Participants interested in attending can join the webcast through the ZOOM link provided. It will feature both audio and a presentation to enrich the viewing experience. Engaging with the speakers during this session is highly encouraged, allowing attendees to pose questions and interact with industry leaders.
Company Background
Founded in 2001, AB Science has rapidly advanced in the pharmaceutical industry by honing its focus on groundbreaking therapies driven by significant medical need. Based in Paris, the company has cultivated a robust portfolio of PKIs and has successfully registered masitinib for veterinary purposes, illustrating the drug's versatility across species.
Commitment to Innovation
AB Science remains committed to pushing the boundaries of science to introduce breakthrough therapies that can change patients' lives. By concentrating on areas with profound unmet needs, the company exemplifies the potential for pharmaceuticals to evolve conventional treatments into more effective options.
Frequently Asked Questions
What is masitinib and its significance?
Masitinib is a protein kinase inhibitor developed by AB Science, targeting conditions like cancers and neurological diseases, representing hope for patients with limited treatment options.
Who are the speakers in the upcoming webcast?
Alain Moussy, the CEO of AB Science, and Olivier Hermine, MD, PhD, will lead the discussions, providing expert insights into masitinib's developments.
How can I attend the webcast?
Interested participants can find the ZOOM link provided in the webcast information and join the event to engage with the speakers.
What is the duration of the webcast?
The webcast is set to run for approximately one hour and fifteen minutes, from 5:30 PM to 6:45 PM CET.
Where is AB Science headquartered?
AB Science is headquartered in Paris, France, and actively contributes to pharmaceutical advancements in the field of targeted therapies.
